Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01298973

Enrollment

Registered

2011-02-18

Start date

2011-01-31

Completion date

2012-01-31

Last updated

2012-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataracts

Brief summary

The purpose of this study is to look at the ability of Viscoat to ensure proper wound closure.

Interventions

DRUGViscoat

One group will receive Viscoat for incision closure

DRUGSaline

One group will receive Saline to irrigate the wound

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Ability to provide informed consent, complete questionnaires, and likely to complete all visits * Subject must be male or female, of any race, and at least 21 years old * Undergoing uncomplicated cataract surgery with clear corneal incisions

Exclusion criteria

* Subjects with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course * Acute or chronic disease or illness that would increase risk or confound study results (e.g., uncontrolled diabetes mellitus, immunocompromised,etc.) * Uncontrolled systemic disease * Corneal abnormalities (e.g., stromal, epithelial or endothelial dystrophies) * Subjects who use concurrent topical or systemic medications that may impair healing, including but not limited to:antimetabolites,isotretinoin (Accutane) within 6 months of treatment, and amiodarone hydrochloride (Cordarone) within 12 months of treatment * Subjects with a history of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine disorders (including but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis * Concurrent participation or participation in the last 30 days in any other clinical trial

Design outcomes

Primary

Measure	Time frame
Ensure watertight, patient wound closure after clear corneal cataract incisions	1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026